Clearmind Medicine Treats 20 Participants in CMND-100 AUD Trial, Advances to Higher Dose Cohort
CMND is trading near its 52-week low of $0.52 (5.8% above the low) on light trading volume (0.1× avg).
Summary
Clearmind Medicine announced a clinical milestone, having treated 20 participants in its Phase I/IIa trial for CMND-100 for Alcohol Use Disorder, with dosing initiated in the higher-dose fourth cohort.
Key Events · Product Development and Regulatory · CMND
-
Clinical Trial Milestone Reached
A total of 20 participants have now been treated across all cohorts in the FDA-approved Phase I/IIa clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD).
-
Advancement to Higher Dose Cohort
Two additional participants have been successfully dosed in the fourth cohort, which features a higher dose of CMND-100 (160 mg), following Data and Safety Monitoring Board (DSMB) approval.
-
Positive Safety Data Continues
The trial continues to demonstrate a favorable safety and tolerability profile, with no serious adverse events reported across the first three cohorts (18 participants).
Analysis · CMND · Life Sciences
This filing details continued progress in Clearmind Medicine's Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder. Reaching 20 treated participants and advancing to a higher dose cohort after positive safety data from previous cohorts is a significant de-risking step for a clinical-stage biotech company. Consistent positive safety and tolerability data are crucial for moving forward in drug development, especially for a company of this size, as it validates the drug's profile and extends its development runway.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.52 to $52.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.